What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: An interpretability study

Y. A. Leshem, T. Hajar, Jon Hanifin, Eric Simpson

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Background The Eczema Area and Severity Index (EASI) is an investigator-assessed instrument measuring the severity of clinical signs in atopic dermatitis (AD). The EASI was identified as one of the best-validated outcome measures for AD; however, no previous studies address how to interpret the EASI score for clinical use. Objectives To evaluate the interpretability and the ease of use of the EASI. Methods A retrospective analysis of paediatric and adult patients with AD was performed. Interpretability was evaluated by stratifying the EASI scores according to the Investigator's Global Assessment. The severity strata displaying the highest kappa coefficient of agreement were then selected as the recommended EASI band. The time to administer the EASI was recorded in a subgroup of patients. Results The suggested severity strata for the EASI are as follows: 0 = clear; 0·1-1·0 = almost clear; 1·1-7·0 = mild; 7·1-21·0 = moderate; 21·1-50·0 = severe; 50·1-72·0 = very severe (κ = 0·75). The EASI was also found to be acceptable in terms of ease of use, with assessments by trained investigators taking approximately 6 min. Conclusions Our study provides the first guide for interpreting the EASI score. It enables translation of the EASI numerical output into an AD global severity state that should be more meaningful to providers and patients. Along with a short administration time, the EASI demonstrates adequate feasibility, further supporting its use in clinical trials. What's already known about this topic? The Eczema Area and Severity index (EASI) is one of the best validated outcome instruments for atopic dermatitis (AD). What does this study add? The severity of AD can now be interpreted from the EASI numerical score. The EASI takes a short time to administer. Our study supports the use of EASI as an outcome tool in clinical trials by providing the first guide for interpreting the score and confirming its ease of use.

Original languageEnglish (US)
Pages (from-to)1353-1357
Number of pages5
JournalBritish Journal of Dermatology
Volume172
Issue number5
DOIs
StatePublished - May 1 2015

Fingerprint

Eczema
Atopic Dermatitis
Research Personnel
Clinical Trials

ASJC Scopus subject areas

  • Dermatology

Cite this

What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis : An interpretability study. / Leshem, Y. A.; Hajar, T.; Hanifin, Jon; Simpson, Eric.

In: British Journal of Dermatology, Vol. 172, No. 5, 01.05.2015, p. 1353-1357.

Research output: Contribution to journalArticle

@article{b08299225fc744b4bfe81846c7b1669e,
title = "What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: An interpretability study",
abstract = "Background The Eczema Area and Severity Index (EASI) is an investigator-assessed instrument measuring the severity of clinical signs in atopic dermatitis (AD). The EASI was identified as one of the best-validated outcome measures for AD; however, no previous studies address how to interpret the EASI score for clinical use. Objectives To evaluate the interpretability and the ease of use of the EASI. Methods A retrospective analysis of paediatric and adult patients with AD was performed. Interpretability was evaluated by stratifying the EASI scores according to the Investigator's Global Assessment. The severity strata displaying the highest kappa coefficient of agreement were then selected as the recommended EASI band. The time to administer the EASI was recorded in a subgroup of patients. Results The suggested severity strata for the EASI are as follows: 0 = clear; 0·1-1·0 = almost clear; 1·1-7·0 = mild; 7·1-21·0 = moderate; 21·1-50·0 = severe; 50·1-72·0 = very severe (κ = 0·75). The EASI was also found to be acceptable in terms of ease of use, with assessments by trained investigators taking approximately 6 min. Conclusions Our study provides the first guide for interpreting the EASI score. It enables translation of the EASI numerical output into an AD global severity state that should be more meaningful to providers and patients. Along with a short administration time, the EASI demonstrates adequate feasibility, further supporting its use in clinical trials. What's already known about this topic? The Eczema Area and Severity index (EASI) is one of the best validated outcome instruments for atopic dermatitis (AD). What does this study add? The severity of AD can now be interpreted from the EASI numerical score. The EASI takes a short time to administer. Our study supports the use of EASI as an outcome tool in clinical trials by providing the first guide for interpreting the score and confirming its ease of use.",
author = "Leshem, {Y. A.} and T. Hajar and Jon Hanifin and Eric Simpson",
year = "2015",
month = "5",
day = "1",
doi = "10.1111/bjd.13662",
language = "English (US)",
volume = "172",
pages = "1353--1357",
journal = "British Journal of Dermatology",
issn = "0007-0963",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis

T2 - An interpretability study

AU - Leshem, Y. A.

AU - Hajar, T.

AU - Hanifin, Jon

AU - Simpson, Eric

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Background The Eczema Area and Severity Index (EASI) is an investigator-assessed instrument measuring the severity of clinical signs in atopic dermatitis (AD). The EASI was identified as one of the best-validated outcome measures for AD; however, no previous studies address how to interpret the EASI score for clinical use. Objectives To evaluate the interpretability and the ease of use of the EASI. Methods A retrospective analysis of paediatric and adult patients with AD was performed. Interpretability was evaluated by stratifying the EASI scores according to the Investigator's Global Assessment. The severity strata displaying the highest kappa coefficient of agreement were then selected as the recommended EASI band. The time to administer the EASI was recorded in a subgroup of patients. Results The suggested severity strata for the EASI are as follows: 0 = clear; 0·1-1·0 = almost clear; 1·1-7·0 = mild; 7·1-21·0 = moderate; 21·1-50·0 = severe; 50·1-72·0 = very severe (κ = 0·75). The EASI was also found to be acceptable in terms of ease of use, with assessments by trained investigators taking approximately 6 min. Conclusions Our study provides the first guide for interpreting the EASI score. It enables translation of the EASI numerical output into an AD global severity state that should be more meaningful to providers and patients. Along with a short administration time, the EASI demonstrates adequate feasibility, further supporting its use in clinical trials. What's already known about this topic? The Eczema Area and Severity index (EASI) is one of the best validated outcome instruments for atopic dermatitis (AD). What does this study add? The severity of AD can now be interpreted from the EASI numerical score. The EASI takes a short time to administer. Our study supports the use of EASI as an outcome tool in clinical trials by providing the first guide for interpreting the score and confirming its ease of use.

AB - Background The Eczema Area and Severity Index (EASI) is an investigator-assessed instrument measuring the severity of clinical signs in atopic dermatitis (AD). The EASI was identified as one of the best-validated outcome measures for AD; however, no previous studies address how to interpret the EASI score for clinical use. Objectives To evaluate the interpretability and the ease of use of the EASI. Methods A retrospective analysis of paediatric and adult patients with AD was performed. Interpretability was evaluated by stratifying the EASI scores according to the Investigator's Global Assessment. The severity strata displaying the highest kappa coefficient of agreement were then selected as the recommended EASI band. The time to administer the EASI was recorded in a subgroup of patients. Results The suggested severity strata for the EASI are as follows: 0 = clear; 0·1-1·0 = almost clear; 1·1-7·0 = mild; 7·1-21·0 = moderate; 21·1-50·0 = severe; 50·1-72·0 = very severe (κ = 0·75). The EASI was also found to be acceptable in terms of ease of use, with assessments by trained investigators taking approximately 6 min. Conclusions Our study provides the first guide for interpreting the EASI score. It enables translation of the EASI numerical output into an AD global severity state that should be more meaningful to providers and patients. Along with a short administration time, the EASI demonstrates adequate feasibility, further supporting its use in clinical trials. What's already known about this topic? The Eczema Area and Severity index (EASI) is one of the best validated outcome instruments for atopic dermatitis (AD). What does this study add? The severity of AD can now be interpreted from the EASI numerical score. The EASI takes a short time to administer. Our study supports the use of EASI as an outcome tool in clinical trials by providing the first guide for interpreting the score and confirming its ease of use.

UR - http://www.scopus.com/inward/record.url?scp=84929130108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929130108&partnerID=8YFLogxK

U2 - 10.1111/bjd.13662

DO - 10.1111/bjd.13662

M3 - Article

C2 - 25580670

AN - SCOPUS:84929130108

VL - 172

SP - 1353

EP - 1357

JO - British Journal of Dermatology

JF - British Journal of Dermatology

SN - 0007-0963

IS - 5

ER -